April 9, 2025: Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients - OncLive - MaaT Pharma

To read the article, click here!

Previous PostApril 9, 2025: MaaT Pharma reports safety interim analysis from trial of microbiome therapy - Clinical Trials Arena
Next PostApril 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club